ClinicalTrials.Veeva

Menu

Multiepitope Peptide Vaccination in Melanoma

Charité University Medicine Berlin logo

Charité University Medicine Berlin

Status and phase

Unknown
Phase 2

Conditions

Metastatic Melanoma

Treatments

Biological: Tyrosinase, MAGE-3, GnTV

Study type

Interventional

Funder types

Other

Identifiers

NCT00153569
HaemaCBFMM03

Details and patient eligibility

About

This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Metastatic melanoma
  • HLA-A1, -A2, -A24, -B44

Exclusion Criteria:

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems